Re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

Temporal offset association between the number of irinotecan-related adverse reactions and pharmacogenomic studies: A cross-correlation analysis

“…Numerous studies have proven that UDP-glucuronosyltransferase 1A1 (UGT1A1, *6, *28 and *93) gene polymorphism was closely related to the occurrence of irinotecan side effects, adjusting its dose under the guidance of UGT1A1 genotype can greatly reduce the incidence and severity of adverse reactions, showed economic advantages and consequently save cost on healthcare systems. ( Argevani et al, 2020 , Carrato, 2022 , Hulshof et al, 2022 , Kong et al, 2022 ).…”